effects on tumor growth, invasion, metabolism, stemness, and promoted apoptosis in subcutaneous and intracranial orthotopic GBM xenograft mouse models, suggesting that peptide compounds based on VDAC1 may become a novel candidate for GBM treatment (73). This evidence concerns the gene VDAC1 and glioblastoma.